Valeant launches Siliq Injection in US

Dermatology unit is rebranded Ortho Dermatologics.

"With the availability of Siliq, physicians have a novel, efficacious treatment option for their adult patients who suffer from moderate-to-severe plaque psoriasis, which can be a truly debilitating, incurable condition," said Joseph C. Papa, chairman and CEO, Valeant. "Additionally, Valeant has priced Siliq as the lowest-priced injectable biologic psoriasis treatment in the US and will work closely with payers to ensure patients have the best possible access to this important new treatment option."

"As the first and only IL-17 receptor A blocker, Siliq is the only product on the market that demonstrated 100% improvement in the psoriasis area and severity index (PASI 100) during the clinical trials as a primary endpoint. In the three clinical trials that have been completed, more than 50% of patients who used Siliq achieved total skin clearance within a year," noted Lawrence J. Green, assistant clinical professor of Dermatology at George Washington University School of Medicine in Washington, D.C. "For my patients that have been suffering with moderate-to-severe plaque psoriasis, having Siliq as an accessible treatment option will make a difference in their day-to-day lives."

Valeant also announced that its dermatology unit will be renamed Ortho Dermatologics, effective immediately, under the new senior leadership team lead by Bill Humphries, executive vice president and company group chairman, Ortho Dermatologics.

"The launch of Siliq is a fitting demonstration of our dermatologic innovation and strong commitment to physicians and their patients. Not only are we bringing a product to market that fulfils a significant unmet medical need, but the pricing of Siliq continues to show our commitment to making our medicines affordable for the patients who need them," said Humphries. "Historically, Ortho Dermatologics was known for high connectivity and partnership with physicians throughout their entire career, and we look forward to continuing to build upon this long-standing legacy."